Kekoolani S Visan
Overview
Explore the profile of Kekoolani S Visan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
68
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lobb R, Visan K, Wu L, Norris E, Hastie M, Everitt S, et al.
Commun Biol
. 2023 Jan;
6(1):68.
PMID: 36653467
Despite significant therapeutic advances, lung cancer remains the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) patients have a very poor overall five-year survival rate of only...
2.
Visan K, Wu L, Voss S, Wuethrich A, Moller A
Semin Cancer Biol
. 2022 Dec;
88:157-171.
PMID: 36581020
Extracellular vesicles (EVs) are nano-sized particles that hold tremendous potential in the clinical space, as their biomolecular profiles hold a key to non-invasive liquid biopsy for cancer diagnosis and prognosis....
3.
Visan K, Lobb R, Ham S, Lima L, Palma C, Edna C, et al.
J Extracell Vesicles
. 2022 Sep;
11(9):e12266.
PMID: 36124834
Small extracellular vesicles (sEVs) provide major promise for advances in cancer diagnostics, prognostics, and therapeutics, ascribed to their distinctive cargo reflective of pathophysiological status, active involvement in intercellular communication, as...
4.
Visan K, Lobb R, Wen S, Bedo J, Lima L, Krumeich S, et al.
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008424
With five-year survival rates as low as 3%, lung cancer is the most common cause of cancer-related mortality worldwide. The severity of the disease at presentation is accredited to the...
5.
Visan K, Lobb R, Moller A
Front Biosci (Landmark Ed)
. 2020 Mar;
25(6):1022-1057.
PMID: 32114423
The progression of a solid cancer from a localised disease to metastatic stages is a key reason for mortality in patients. Amongst the drivers of cancer progression, pithelial-to-esenchymal ransition (EMT)...